Related Experiment Video
Updated: Aug 20, 2025
06:19
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
937
The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection
Nasser A Fugara1, Zaineh A Shawareb1, Nancy K Rakkad1
1Ophthalmology, King Hussein Medical Center, Royal Medical Services of Jordanian Armed Forces, Amman, JOR.
Cureus
|November 18, 2022
Summary
Diabetic patients receiving intravitreal bevacizumab injections face an increased risk of non-arteritic ischemic optic neuropathy. This risk is particularly elevated for those undergoing three or more injections.
Area of Science:
- Ophthalmology
- Diabetology
- Vascular Neurology
Background:
- Diabetic retinopathy is a leading cause of vision loss.
- Intravitreal bevacizumab is a common treatment for diabetic eye conditions.
- Non-arteritic ischemic optic neuropathy (NAION) is a potential complication affecting vision.
Purpose of the Study:
- To determine the incidence of NAION in diabetic patients treated with intravitreal bevacizumab.
- To compare NAION rates between diabetic patients receiving intravitreal bevacizumab and those receiving alternative treatments.
Main Methods:
- A prospective comparative study was conducted over one year.
- Diabetic patients were divided into two groups: those receiving intravitreal bevacizumab and those not.
- NAION incidence was recorded and compared between groups.
Main Results:
- The incidence of NAION was higher in the intravitreal bevacizumab group (49/2468) compared to the control group (68/7375).
- Most NAION cases occurred in patients who received three or more bevacizumab injections.
- Statistical significance was assessed using P-values (≤0.05).
Conclusions:
- Intravitreal bevacizumab is a risk factor for developing NAION in diabetic patients.
- The risk of NAION increases with the number of bevacizumab injections, especially after three or more.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
521
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
521
01:25Glaucoma: Overview
689
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
689
01:28Angle Closure Glaucoma: Treatment
617
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
617